CLAIMS

1. Use of a compound of the following formula (I)



(I)

wherein

- R1 is a hydrogen atom or a halogen atom;
- R2 is a cyclohexyle or a phenyl;
- R3 is a cycloalkyl having 3 to 6 carbon atoms;
- R4 is a hydrogen atom, an alkyl having 1 to 6 carbon atom or acycloalkyl having 3 to 6 carbon atoms;
- A is a group selected from –CO-CH_2-, -CH(Cl)-CH_2-, -CH(OH)-CH_2-, -CH_2-CH_2-, -CH=CH-, -C≡C-,

or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof in the manufacture of a medicament for preventing or treating an infection by a virus in an individual.

2. The use according to claim 1, wherein wherein the compound of formula (I) is selected from the group consisting of:






Cl
N


Cl
N
O


Cl
N


Cl
N


Cl
N


Cl
N
OH



3. The use according to claim 1 or 2, wherein the compound of formula (I) is SR-31747.

4. The use according to any one of claims 1 to 3, wherein the virus is of the *Coronaviridae* family, more particularly of the *Betacoronavirus* genus.

5. The use according to any one of claims 1 to 4, wherein the virus is selected from the group consisting of SARS-CoV, SARS-CoV-2, MERS-CoV and mutants or variants thereof.

6. The use according to any one of claims 1 to 5, wherein the virus is SARS-CoV-2, or a mutant or variant thereof.

7. The use according to any one of claims 1 to 6, wherein the individual is aged 50 or more.

8. The use according to any one of claims 1 to 7, wherein the individual suffers from at least one other disease or condition, in particular selected from hypertension, diabetes, a cardiovascular disease, a chronic respiratory disease, or cancer.

9. The use according to any one of claims 1 to 8, wherein the medicament is to be administered in combination with at least one other compound suitable for the prevention or treatment of an infection by a virus.

10. The use of a pharmaceutical composition, comprising as active substance a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in the manufacture of a medicament for preventing or treating an infection by a virus in an individual.

11. The use according to claim 10, wherein the virus is of the *Coronaviridae* family, more particularly of the *Betacoronavirus* genus.

12. The use according to claim 10 or 11, wherein the virus is selected from the group consisting of SARS-CoV, SARS-CoV-2, MERS-CoV and mutants or variants thereof.

13. The use according to any one of claims 10 to 12, wherein the virus is SARS-CoV-2, or a mutant or variant thereof.

14. The use according to any one of claims 10 to 13, further comprising at least one other compound suitable for the prevention or treatment of an infection by a virus.

15. Use of a product comprising:
- a compound of formula (I) or a pharmaceutically acceptable salt, ester, hydrate, derivative, prodrug or metabolite thereof, and
- at least one other compound suitable for the prevention or treatment of an infection by a virus,

in a preparation of a combined medicament for simultaneous, separate, or sequential use in the prevention or treatment of an infection by a virus in an individual.